Literature DB >> 3006244

Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions.

J Sodroski, W C Goh, C Rosen, A Tartar, D Portetelle, A Burny, W Haseltine.   

Abstract

The genome of the human T-lymphotropic virus type III (HTLV-III/LAV) has the potential to encode at least three polypeptides in addition to those encoded by the gag, pol, and env genes. In this study, the product of the sor (short open reading frame) region, which overlaps the 3' end of the pol gene, was found to be a protein with a molecular weight of 23,000. An assay was developed for testing the ability of cloned HTLV-III proviruses to produce viruses cytopathic for T4+ lymphocytes. In the cell line used, C8166, neither the HTLV-III sor gene product nor the complete 3'-orf gene product were necessary for the replication or cytopathic effects of the HTLV-III.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3006244     DOI： 10.1126/science.3006244

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  82 in total

1.  Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro.

Authors:  M Kotler; M Simm; Y S Zhao; P Sova; W Chao; S F Ohnona; R Roller; C Krachmarov; M J Potash; D J Volsky
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 2.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

3.  Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag.

Authors:  P Sova; D J Volsky; L Wang; W Chao
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes.

Authors:  D H Gabuzda; K Lawrence; E Langhoff; E Terwilliger; T Dorfman; W A Haseltine; J Sodroski
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

5.  Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication.

Authors:  Fei Guo; Shan Cen; Meijuan Niu; Jenan Saadatmand; Lawrence Kleiman
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

6.  Envelope glycoprotein and CD4 independence of vpu-facilitated human immunodeficiency virus type 1 capsid export.

Authors:  X J Yao; H Göttlinger; W A Haseltine; E A Cohen
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

Review 7.  Lentiviral Vif: viral hijacker of the ubiquitin-proteasome system.

Authors:  Elana S Ehrlich; Xiao-Fang Yu
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

8.  Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by a two-amino-acid insertion in HIV-1 Vif from a nonprogressing mother and child.

Authors:  Louis Alexander; Mary Janette Aquino-DeJesus; Michael Chan; Warren A Andiman
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Genetic variability between isolates of human immunodeficiency virus (HIV) type 2 is comparable to the variability among HIV type 1.

Authors:  J F Zagury; G Franchini; M Reitz; E Collalti; B Starcich; L Hall; K Fargnoli; L Jagodzinski; H G Guo; F Laure
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

10.  Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains.

Authors:  J Goncalves; B Shi; X Yang; D Gabuzda
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.